ANALYTISCHE STRATEGIE Tissue Imaging. Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich
|
|
- Monica Evans
- 5 years ago
- Views:
Transcription
1 ANALYTISCHE STRATEGIE Tissue Imaging Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich
2 Quantitative Breast single cancer cell analysis Switzerland Brain Breast Lung Colon-rectum Pancreas Ovary New cases Deaths Lung Liver Primary tumor Bones # cases Metastatic breast cancer 2
3 Quantitative Breast single cancer cell analysis lobe ducts normal lobules non-invasive fat tissue 3
4 Silencing of kinases Tumor heterogeneity: can induce Quantitative single cell analysis cell state heterogeneity Intra-tumor heterogeneity Cancer stem cell (CSC) - Differential treatment response of clones - Responsible for future events, e.g. metastasis (EMT) Nat Rev Cancer Apr 19;12(5):
5 Silencing of kinases Tumor heterogeneity: can induce Quantitative single cell analysis cell state heterogeneity Inter-tumor heterogeneity Patients of same classification, e.g. HER2 + - Differential treatment response and prognosis between patients - Better classification needed Nat Rev Cancer Apr 19;12(5):
6 Infiltrating normal cells: Quantitative single cell analysis Tumor as an organ - Diverse cells contribute to tumor development - Tumor microenvironment (TME) induces CSCs, EMT,.. Nat Rev Cancer Apr 19;12(5):
7 Why is understanding the tumor Quantitative single cell analysis composition and structure important? Subopulations CSCs TME cell types (TAMs) Cell-cell interactions Clinical data Biomarkers/ classification Targeting all cells & TME Subpopulation biology NEED FOR MULTIPLEXED IMAGING 7
8 Quantitative Question single cell 1: analysis Classification of most cancer patients currently relies on an experience-based assessment of biomarker distribution and tumor morphology by a pathologist. The marker distribution and morphology is typically visualized by immunohistochemical methods. How many markers are analyzed in breast cancer and how reproducible are the classifications by a pathologist? 8
9 PR expression on a breast cancer tissue Quantitative single cell analysis microarray 9
10 PR expression on a breast cancer tissue Quantitative single cell analysis microarray Where do you set the threshold? 10
11 Quantitative Question single cell 1: analysis Possible answer Subtype ER PR HER2 Therapy normal-like anthracylines, taxanes luminal A endocrine therapy luminal B + + +/- endocrine therapy HER2-positive growth factor receptor inhibitors triple negative PARP inhibitors, platinum salts Resistance Relapse Metastasis Agreement among pathologist between 70%-90% depending on type/question. But: no gold standard to test against available! 11
12 Quantitative Question single cell 1: analysis Possible answer But more subtypes exist, currently prognosis not accurately determined! 12
13 Quantitative Question single cell 2a: analysis Recently, three novel methods to visualize tumor samples in a highly multiplexed manner were published, including two imaging mass spectrometry based approaches. A) What promise do these methods hold for a personalized patient classification? B) What are the strengths and weaknesses of each of these methods? C) How could imaging mass cytometry, the LA-ICP-MS based imaging method, find its way into clinical practice? For clinical use, the technology must be fast, reliable, and affordable. D) What tissue features imaged by LA-ICP-MS could be used as biomarkers? 13
14 Quantitative Question single cell 2a: analysis 1. More markers for more accurate classification (akin to genomics). 2. Additional probes for classification, e.g. genomic features (FISH). 3. Biomarkers that guide therapy (e.g. HER2). 4. Biomarkers that reveal the biology and thus treatment plans (see D). 14
15 Quantitative Question single cell 2b: analysis Recently, three novel methods to visualize tumor samples in a highly multiplexed manner were published, including two imaging mass spectrometry based approaches. A) What promise do these methods hold for a personalized patient classification? B) What are the strengths and weaknesses of each of these methods? C) How could imaging mass cytometry, the LA-ICP-MS based imaging method, find its way into clinical practice? For clinical use, the technology must be fast, reliable, and affordable. D) What tissue features imaged by LA-ICP-MS could be used as biomarkers? 15
16 Quantitative LA-ICP-MS single cell analysis Koch J. et al., Applied Spectroscopy
17 Quantitative The single mass cell cytometer: analysis CyTOF 3. Time-of-flight (TOF) ion separation and detection 2. Ion filtering 1. Sample introduction and ionization Bandura D. et al., Anal. Chem
18 Quantitative Ion single separation cell analysis Push-out plate: ions pushed into TOF chamber at 13 µsec intervals ( pushes )
19 Quantitative Laser single ablation cell analysis system 20 Hz ablation CyTOF Intensity Time Hao Wang and Detlef Guenther Wang HAO et al., Anal. Chem
20 Quantitative Workflow single cell imaging analysis mass cytometry Giesen C., Wang HAO et al. Nat. Methods
21 Quantitative Validation single cell of analysis approach Giesen C., Wang HAO et al. Nat. Methods
22 Quantitative nano-sims single cell analysis based tissue imaging Angelo M. et al., Nat. Med
23 Quantitative Serial single IFM cell analysis Gerdes MJ. et al., PNAS
24 Quantitative Question single cell 2b: analysis LA-ICP-MS Nano-SIMS Serial IFM Resolution 1000 nm 100 nm 200 nm-300 nm Multiplexing 120 (44) 7(7)/Serial 61(3)/Serial Repeat scanning No / serial section Quantitative Yes* No Yes* Ease of use Medium Low High Through put Yes Yes ~6 hrs / mm 2 ~6 hrs / mm 2 66 hrs / 500 mm 2 Cost High Very high Low Sensitivity *Need of appropriate standards None is applicable to clinical practice 24
25 Quantitative Question single cell 2c: analysis Recently, three novel methods to visualize tumor samples in a highly multiplexed manner were published, including two imaging mass spectrometry based approaches. A) What promise do these methods hold for a personalized patient classification? B) What are the strengths and weaknesses of each of these methods? C) How could imaging mass cytometry, the LA-ICP-MS based imaging method, find its way into clinical practice? For clinical use, the technology must be fast, reliable, and affordable. D) What tissue features imaged by LA-ICP-MS could be used as biomarkers? 25
26 Quantitative Question single cell 2c: analysis 1. Centralized large facilities. 2. Instruments must be developed that are robust and self monitoring. 3. LA-ICP-MS for dummies. 4. Instruments should be cheaper (though this matters less than you think). 5. Increased throughput: not hours, but minutes per tissue. 6. Most informative antibodies must be determined for classification. 7. Antibody panels must be validated and approved. 8. Appropriate standards must be developed. 9. Algorithms need to be developed to analyze this high dimensional data for patient classification. 10. Biomarkers that reveal the biology and thus treatment plans (see c). 11. Pathologist will only look at cases in which algorithms struggled. 12. Clinicians/pathologists must accept such a new approach (this matters more than you think). 26
27 Quantitative Question single cell 2d: analysis Recently, three novel methods to visualize tumor samples in a highly multiplexed manner were published, including two imaging mass spectrometry based approaches. A) What promise do these methods hold for a personalized patient classification? B) What are the strengths and weaknesses of each of these methods? C) How could imaging mass cytometry, the LA-ICP-MS based imaging method, find its way into clinical practice? For clinical use, the technology must be fast, reliable, and affordable. D) What tissue features imaged by LA-ICP-MS could be used as biomarkers? 27
28 Luminal B Her2 Quantitative single cell analysis + breast cancer (8/32 markers shown) Besides proteins and p-sites: - Genome mutations (FISH) - Epigenetics a: CK8/18, H3, Vimentin - Transcripts b: CK7, H3, CD44 - Metabolites c: Pan-actin, PR, CD68 - Directly metals - Etc. Giesen C., Wang HAO et al. Nat. Methods
29 Cell subpopulations present Quantitative single cell analysis in 21 breast cancer patients Patient classification based on cell states Giesen C., Wang HAO et al. Nat. Methods
30 Intra- and inter-patient Quantitative single cell analysis tumor heterogeneity TN Normal Luminal HER2- Luminal HER2+ HER2+ TN HER2+ Luminal HER2+ Giesen C., Wang HAO et al. Nat. Methods
31 Quantitative Classification single cell analysis of patients 31
32 Quantitative Question single cell 2d: analysis Subopulations CSCs TME cell types (TAMs) Cell-cell interactions Clinical data Biomarkers/ classification Targeting all cells & TME Subpopulation biology 32
33 Quantitative Question single cell 3: analysis Describe analytical strategies to determine the absolute copy number of the analyzed biomarkers per cell in a tissue section using imaging mass cytometry. Of note, a typical tissue section has a thickness between 2-4 micrometers. The thickness variability is up to 50% within a given tissue section. 33
34 Quantitative Question single cell 3: analysis What do we need First we need to make sure LA-ICP-MS is quantitative: 1. Representative sampling: a representative aerosol composition <200 nm lasers (e.g. ArF eximer) 2. High transport efficiencies of all particles: Ideally homogenous size distribution 3. Representative (complete) decomposition, ionization and sampling of particles that reach the ICP 4. Mass spectrometer must be quantitative over the analyzed dynamic range 34
35 Quantitative Question single cell 3: analysis What do we need First we need to make sure LA-ICP-MS is quantitative: 1. Representative sampling: a representative aerosol composition <200 nm lasers (e.g. ArF eximer) 2. High transport efficiencies of all particles: Ideally homogenous size distribution 3. Representative (complete) decomposition, ionization and sampling of particles that reach the ICP 4. Mass spectrometer must be quantitative over the analyzed dynamic range 35
36 Quantitative Question single cell 3: analysis What do we need First we need to make sure LA-ICP-MS is quantitative: 1. Representative sampling: a representative aerosol composition <200 nm lasers (e.g. ArF eximer) 2. High transport efficiencies of all particles: Ideally homogenous size distribution 3. Representative (complete) decomposition, ionization and sampling of particles that reach the ICP 4. Mass spectrometer must be quantitative over the analyzed dynamic range 36
37 Quantitative Question single cell 3: analysis What do we need Standards: 1. Internal standard correct for the drift in sensitivity, matrix effects, and the ablated mass, in our case tissue thickness. Requirements: Equal distribution in tissue Same behaviour as analytes 2. Matrix matched external standard 3. (Non-matrix matched external standards) but two problems remain 37
38 [Antibody] Quantitative Antibodies single cell analysis are NOT quantitative ABs [c] dependent Epitope accessibility Background binding Binding site occupancy Intensity Antibody labeling Polyclonal antibodies Antibody binding (capacity) epitope copy number 38
39 Need to generate an external calibrant for Quantitative single cell analysis every AB Calibrate still one problem remains 39
40 Quantitative A single tissue cell section analysis only part of a cell D reconstruction needed to quantify per cell expression 40
41 Quantitative Question single cell 4: analysis What advantages does absolute copy number quantification have over relative quantification for patient classification? 41
42 Quantitative Question single cell 4: analysis Standardization -ABs -labs Copy numbers to diagnose Defines thresholds So far classification is subjective Different datasets cannot be compared 42
43 Quantitative Question single cell 5: analysis Some clinically relevant proteins are present at less than 100 proteins per single cell. The CyTOF mass cytometer can detect ~1 out of 10,000 ions generated in the plasma; in imaging mass cytometry a single cell contains ~400 measurement points; and an antibody on average is coupled to 100 lanthanide ions. Describe strategies that could be used to detect such low abundance proteins by imaging mass cytometry. 43
44 Quantitative Question single cell 5: analysis We need to increase the signal (S/N)! 1. Protein localization? 2. Increase tissue thickness to whole cell (problems with that?). 3. Increase laser spot size. 4. Reduce sample loss during transport. 5. Use antibodies that target different epitopes on same protein. 6. Increase number of metals bound per antibody. 7. Improve instruments sensitivity. 8. Your ideas. 9. Etc. 44
Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry
Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationSpatially resolved multiparametric single cell analysis. Technical Journal Club 19th September 2017 Christina Müller (Group Speck)
Spatially resolved multiparametric single cell analysis Technical Journal Club 19th September 2017 Christina Müller (Group Speck) Why spatially resolved multiparametric single cell analysis? Multiparametric
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationTowards High Resolution MS in Regulated Bioanalysis
Towards High Resolution MS in Regulated Bioanalysis Benno Ingelse MSD 3 rd EB focus meeting June 12 th 13 th Brussels, Belgium Contributors Gary Adamson Ken Anderson Kevin Bateman Cynthia Chavez-Eng Inhou
More information* * * * Supplementary Figure 1. DS Lv CK HSA CK HSA. CK Col-3. CK Col-3. See overleaf for figure legend. Cancer cells
Supplementary Figure 1 Cancer cells Desmoplastic stroma Hepatocytes Pre-existing sinusoidal blood vessel New blood vessel a Normal liver b Desmoplastic HGP c Pushing HGP d Replacement HGP e f g h i DS
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationBiobanking of Breast Cancer: Ultimately leading to prevention of brain metastases
Biobanking of Breast Cancer: Ultimately leading to prevention of brain metastases A.Hoeben, MD PhD Medical Oncologist Content. Introduction: -> need to optimize current treatment options for brain metastasized
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationThe time has come: SINGLE CELL western blotting. Parrinello Natalia TJC
The time has come: SINGLE CELL western blotting Parrinello Natalia TJC 08.07.2014 To fully understand diverse and often rare behaviors in complex cell populations, researchers need analytical tools that:
More informationDOWNLOAD OR READ : UNDERSTANDING BREAST CANCER CELL BIOLOGY AND THERAPY A VISUAL APPROACH PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : UNDERSTANDING BREAST CANCER CELL BIOLOGY AND THERAPY A VISUAL APPROACH PDF EBOOK EPUB MOBI Page 1 Page 2 understanding breast cancer cell biology and therapy a visual approach understanding
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationProteomic Biomarker Discovery in Breast Cancer
Proteomic Biomarker Discovery in Breast Cancer Rob Baxter Laboratory for Cellular and Diagnostic Proteomics Kolling Institute, University of Sydney, Royal North Shore Hospital robert.baxter@sydney.edu.au
More informationAccurate and Affordable Allergen Quantification for the Seed Biotech Industry
Accurate and Affordable Allergen Quantification for the Seed Biotech Industry Inventors Jay J. Thelen, PhD, Severin E. Stevenson, MS University of Missouri, Department of Biochemistry What is the problem?
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationMass Cytometry Publication List
Mass Cytometry Publication List 2014 Publications 1 Becher, B., et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol 15 (12): 1181-1189, 2014. Behbehani, G.K., et al. Transient
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationUsing Histoindex Genesis 200 imaging technology to analyse the Pattern of ECM Deposition in Human Breast Cancer Tissue
Using Histoindex Genesis 200 imaging technology to analyse the Pattern of ECM Deposition in Human Breast Cancer Tissue Introduction to technology High Resolution Detects fine collagen fibers up to 0.1µm
More informationa RT:. - 1.1 1 95 9 85 8 27.64 27.87 28.1 27.42 28.24 38.98 Low ph RPLC NL: 2.29E9 TIC MS TrypticBSA_Dig est_replicate1_ 2Mar18_Preci ous_18-1-6 75 7 65 48.75 65.8 Relative Abundance 6 55 5 45 28.54 48.98
More informationION MOBILITY COUPLED TO HIGH RESOLUTION MASS SPECTROMETRY: THE POSSIBILITIES, THE LIMITATIONS
ION MOBILITY COUPLED TO HIGH RESOLUTION MASS SPECTROMETRY: THE POSSIBILITIES, THE LIMITATIONS Anton Kaufmann Official Food Control Authority of the Canton of Zurich (Kantonales Labor Zürich) Switzerland
More informationDigitizing the Proteomes From Big Tissue Biobanks
Digitizing the Proteomes From Big Tissue Biobanks Analyzing 24 Proteomes Per Day by Microflow SWATH Acquisition and Spectronaut Pulsar Analysis Jan Muntel 1, Nick Morrice 2, Roland M. Bruderer 1, Lukas
More informationMALDI Imaging Drug Imaging Detlev Suckau Head of R&D MALDI Bruker Daltonik GmbH. December 19,
MALDI Imaging Drug Imaging Detlev Suckau Head of R&D MALDI Bruker Daltonik GmbH December 19, 2014 1 The principle of MALDI imaging Spatially resolved mass spectra are recorded Each mass signal represents
More informationIon Source. Mass Analyzer. Detector. intensity. mass/charge
Proteomics Informatics Overview of spectrometry (Week 2) Ion Source Analyzer Detector Peptide Fragmentation Ion Source Analyzer 1 Fragmentation Analyzer 2 Detector b y Liquid Chromatography (LC)-MS/MS
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationINTRODUCTION TO MALDI IMAGING
INTRODUCTION TO MALDI IMAGING Marten F. Snel, Emmanuelle Claude, Thérèse McKenna, and James I. Langridge Waters Corporation, Manchester, UK INT RODUCTION The last few years have seen a rapid increase in
More informationScreening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery
Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies
More informationLC/MS/MS SOLUTIONS FOR LIPIDOMICS. Biomarker and Omics Solutions FOR DISCOVERY AND TARGETED LIPIDOMICS
LC/MS/MS SOLUTIONS FOR LIPIDOMICS Biomarker and Omics Solutions FOR DISCOVERY AND TARGETED LIPIDOMICS Lipids play a key role in many biological processes, such as the formation of cell membranes and signaling
More informationIntroduction to Proteomics 1.0
Introduction to Proteomics 1.0 CMSP Workshop Pratik Jagtap Managing Director, CMSP Objectives Why are we here? For participants: Learn basics of MS-based proteomics Learn what s necessary for success using
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationProfili di espressione genica
Profili di espressione genica Giampaolo Bianchini MD Ospedale San Raffaele, Milan - Italy Gene expression profiles Transcriptomics Gene DNA mrna mirnas Protein metilation Metabolite Genomics Transcriptomics
More informationHigh-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine
High-Throughput Quantitative LC-MS/MS Analysis of and 14 Benzodiazepines in Urine Bill Yu, Kristine Van Natta, Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 588 Key Words Opiates,
More informationSolving practical problems. Maria Kuhtinskaja
Solving practical problems Maria Kuhtinskaja What does a mass spectrometer do? It measures mass better than any other technique. It can give information about chemical structures. What are mass measurements
More informationDavid M. Rocke Division of Biostatistics Department of Public Health Sciences University of California, Davis
David M. Rocke Division of Biostatistics Department of Public Health Sciences University of California, Davis Biomarkers Tissue (gene/protein/mirna) Invasive Only useful post-surgery/biopsy Gold standard
More informationMetabolomics: quantifying the phenotype
Metabolomics: quantifying the phenotype Metabolomics Promises Quantitative Phenotyping What can happen GENOME What appears to be happening Bioinformatics TRANSCRIPTOME What makes it happen PROTEOME Systems
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationElizabeth Crawford 1, Shaoxia Yu 2, Lawrence Cohen 2 Justin Gordon 2, Brian Musselman 1, Jing-Tao Wu 2. IonSense, Inc., Saugus, MA
Eliminating Method Development, Sample Preparation and Chromatographic Separations in High-Throughput Bioanalysis Using DART on an Enhanced Resolution Triple-Quadrupole Mass Spectrometer Elizabeth Crawford
More informationCellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA
Cellecta Overview Started Operations in 2007 Headquarters: Mountain View, CA Focus: Development of flexible, scalable, and broadly parallel genetic screening assays to expedite the discovery and characterization
More informationBreast cancer pathology
Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters
More informationGaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017
Gaining New Insights Through IF Multiplexed Staining and Analysis Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory Assessing more from Tissue Sections Gaps with More Common Methods Most common
More informationCancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
More informationAbsoluteIDQ p150 Kit. Targeted Metabolite Identifi cation and Quantifi cation. Bringing our targeted metabolomics expertise to your lab.
AbsoluteIDQ p150 Kit Targeted Metabolite Identifi cation and Quantifi cation Bringing our targeted metabolomics expertise to your lab. The Biocrates AbsoluteIDQ p150 mass spectrometry Assay Preparation
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationApplication Note # MT-111 Concise Interpretation of MALDI Imaging Data by Probabilistic Latent Semantic Analysis (plsa)
Application Note # MT-111 Concise Interpretation of MALDI Imaging Data by Probabilistic Latent Semantic Analysis (plsa) MALDI imaging datasets can be very information-rich, containing hundreds of mass
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2
More informationApplication Note # LCMS-89 High quantification efficiency in plasma targeted proteomics with a full-capability discovery Q-TOF platform
Application Note # LCMS-89 High quantification efficiency in plasma targeted proteomics with a full-capability discovery Q-TOF platform Abstract Targeted proteomics for biomarker verification/validation
More informationType of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationThe Detection of Allergens in Food Products with LC-MS
The Detection of Allergens in Food Products with LC-MS Something for the future? Jacqueline van der Wielen Scope of Organisation Dutch Food and Consumer Product Safety Authority: Law enforcement Control
More informationRegarding techniques of proteomics, there is:
Molecular الحلقة biology 14 واألخيرة To put you back in the context; the discussion was about Trancriptomics (the study of transcription). The following topic will be PROTEOMICS, which is the study of
More informationCancer Biology Course. Invasion and Metastasis
Cancer Biology Course Invasion and Metastasis 2016 Lu-Hai Wang NHRI Cancer metastasis Major problem: main reason for killing cancer patients, without it cancer can be cured or controlled. Challenging questions:
More informationTITLE: Early Lung Cancer Detection via Global Protein Modification Profiles
AD Award Number: W81XWH-12-1-0310 TITLE: Early Lung Cancer Detection via Global Protein Modification Profiles PRINCIPAL INVESTIGATOR: Augusto Lois CONTRACTING ORGANIZATION: Sanford-Burnham Medical Research
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationBruker Daltonics. autoflex III smartbeam. The Standard in MALDI-TOF Performance MALDI-TOF/TOF. think forward
Bruker Daltonics autoflex III smartbeam The Standard in MALDI-TOF Performance think forward MALDI-TOF/TOF Designed for a Routine High Level of Performance The autoflex III smartbeam brings the power of
More informationPathology of Inflammatory Breast Cancer (IBC) A rare tumor
Pathology of Inflammatory Breast Cancer (IBC) A rare tumor Jelle Wesseling 1, John Martens 2, Gabe Sonke 1, Carolien Schröder 3 1: Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam
More informationLECTURE-15. itraq Clinical Applications HANDOUT. Isobaric Tagging for Relative and Absolute quantitation (itraq) is a quantitative MS
LECTURE-15 itraq Clinical Applications HANDOUT PREAMBLE Isobaric Tagging for Relative and Absolute quantitation (itraq) is a quantitative MS based method for quantifying proteins subject to various different
More information2017 Breast Cancer Update
2017 Breast Cancer Update Alberto J Montero, M.D., MBA Quality Improvement Officer, Taussig Cancer Institute, Lerner College of Medicine Cleveland Clinic N/A Disclosure Overview Epidemiology (US/Global)
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationSupplementary Figure 1. Identification of tumorous sphere-forming CSCs and CAF feeder cells. The LEAP (Laser-Enabled Analysis and Processing)
Supplementary Figure 1. Identification of tumorous sphere-forming CSCs and CAF feeder cells. The LEAP (Laser-Enabled Analysis and Processing) platform with laser manipulation to efficiently purify lung
More informationImmune Cell Phenotyping in Solid Tumors using Quantitative Pathology
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationIn-stream attenuation of neuro-active pharmaceuticals and their
In-stream attenuation of neuro-active pharmaceuticals and their metabolites Supporting Information Analytical Methods and Figures (10 pages) Jeffrey H. Writer, Ronald C. Antweiler, Imma Ferrer, Joseph
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationEDXRF APPLICATION NOTE
EDXRF APPLICATION NOTE ANALYSIS OF ANIMAL FEEDS # 1279 SCOPE The analysis of finished animal feeds and premixes is demonstrated using EDXRF with indirect excitation and Fundamental Parameters software,
More informationNon-Traditional Approaches to MALDI- TOF Mass Spectrometry Analysis of Low Molecular Weight Polymers
Non-Traditional Approaches to MALDI- TOF Mass Spectrometry Analysis of Low Molecular Weight Polymers Justin R. Engle and S. Kim R. Williams Laboratory for Advance Separation Technologies Department of
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationProteomics of body liquids as a source for potential methods for medical diagnostics Prof. Dr. Evgeny Nikolaev
Proteomics of body liquids as a source for potential methods for medical diagnostics Prof. Dr. Evgeny Nikolaev Institute for Biochemical Physics, Rus. Acad. Sci., Moscow, Russia. Institute for Energy Problems
More informationSUPPLEMENTAY FIGURES AND TABLES
SUPPLEMENTAY FIGURES AND TABLES Supplementary Figure S1: Validation of mir expression by quantitative real-time PCR and time course studies on mir- 29a-3p and mir-210-3p. A. The graphs illustrate the expression
More informationAn optical dosimeter for the selective detection of gaseous phosgene with ultra-low detection limit
Supporting information for An optical dosimeter for the selective detection of gaseous phosgene with ultra-low detection limit Alejandro P. Vargas, Francisco Gámez*, Javier Roales, Tània Lopes-Costa and
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationSCIENCE WEBINAR. Autoantibody Biomarkers for Cancer and Autoimmune Disease. Eng M Tan, M. D. The Scripps Research Institute La Jolla, California
SCIENCE WEBINAR Autoantibody Biomarkers for Cancer and Autoimmune Disease Eng M Tan, M. D. The Scripps Research Institute La Jolla, California Systemic Lupus Erythematosus The Prototype Autoimmune Disease
More informationMS1 and MS2 crosstalk in label free quantitation of mass spectrometry data independent acquisitions
MS1 and MS2 crosstalk in label free quantitation of mass spectrometry data independent acquisitions MS1 528.18 +++ m/z 568.98 ++ m/z 678.34 ++ m/z MS2/SWATH June 9th, 2013 Matthew J. Rardin SIRT3 regulated
More informationAbstract. Background. Objective
Molecular epidemiology of clinical tissues with multi-parameter IHC Poster 237 J Ruan 1, T Hope 1, J Rheinhardt 2, D Wang 2, R Levenson 1, T Nielsen 3, H Gardner 2, C Hoyt 1 1 CRi, Woburn, Massachusetts,
More informationMatrix Assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry
Matrix Assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry Time-of-Flight Mass Spectrometry. Basic principles An attractive feature of the time-of-flight (TOF) mass spectrometer is its
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More information1. Sample Introduction to MS Systems:
MS Overview: 9.10.08 1. Sample Introduction to MS Systems:...2 1.1. Chromatography Interfaces:...3 1.2. Electron impact: Used mainly in Protein MS hard ionization source...4 1.3. Electrospray Ioniztion:
More informationExosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study
GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong
More informationIntegrated Targeted Quantitation Method for Insulin and its Therapeutic Analogs
Integrated Targeted Quantitation Method for Insulin and its Therapeutic Analogs Eric Niederkofler, 1 Dobrin Nedelkov, 1 Urban Kiernan, 1 David Phillips, 1 Kemmons Tubbs, 1 Scott Peterman, 2 Bryan Krastins,
More informationEarly dissemination in prostate cancer
Early dissemination in prostate cancer Miodrag Guzvic, University of Regensburg, Germany Adjuvant Palliative M0 Initiation Diagnosis Surgery Metastasis Death Intervention window to delay or prevent metastasis
More informationTissue Distribution/Penetration and Pharmacokinetics of CD101
Tissue Distribution/Penetration and Pharmacokinetics of CD0 Yanan Zhao, Brendan Prideaux, Pei-Yu Chen, Yoji Nagasaki, Min Hee Lee, Grayson Hough, Voon Ong, Veronique Dartois, David S. Perlin Public Health
More informationAnaly?cal strategy. Tissue imaging. Prof. Detlef Günther Prof. Renato Zenobi. Sahar Ghiasikhou Kaspar Andreas Kuster Beatrice
Analy?cal strategy Tissue imaging Prof. Detlef Günther Prof. Renato Zenobi Sahar Ghiasikhou Kaspar Andreas Kuster Beatrice 04.11.14 Introduc?on Cellular imaging Mul?disciplinary techniques that detects
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationMALDI-TOF Mass Spectrometry: A New Rapid ID Method in Clinical Microbiology
MALDI-TOF Mass Spectrometry: A New Rapid ID Method in Clinical Microbiology Patrick R. Murray, PhD WW Director, Scientific Affairs BD Diagnostic Systems Outline MALDI-TOF is the most important innovation
More informationJoachim Eberle Head of R&D, Roche Centralized Diagnostics
Workshop Roche Diagnostics and Biomarker Development Joachim Eberle Head of R&D, Roche Centralized Diagnostics Biomarkers and Roche Making a Diagnostics test Current rograms 2 Why is Roche interested in
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationFundamentals of Soft Ionization and MS Instrumentation
Fundamentals of Soft Ionization and MS Instrumentation Ana Varela Coelho varela@itqb.unl.pt Mass Spectrometry Lab Analytical Services Unit Index Mass spectrometers and its components Ionization methods:
More informationAn Alternative Approach: Top-Down Bioanalysis of Intact Large Molecules Can this be part of the future? Lecture 8, Page 27
An Alternative Approach: Top-Down Bioanalysis of Intact Large Molecules Can this be part of the future? Lecture 8, Page 27 Top-down HRAM Bioanalysis of Native Proteins/Molecules Relative Abundance 100
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationNew Mass Spectrometry Tools to Transform Metabolomics and Lipidomics
New Mass Spectrometry Tools to Transform Metabolomics and Lipidomics July.3.13 Ken Miller Vice President of Marketing, Life Sciences Mass Spectrometry 1 The world leader in serving science Omics & the
More information